{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T10:55:50Z","timestamp":1759056950513,"version":"3.44.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.jneuroim.2015.07.013","type":"journal-article","created":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T18:55:40Z","timestamp":1438196140000},"page":"16-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Increased serum peroxiredoxin 5 levels in myasthenia gravis"],"prefix":"10.1016","volume":"287","author":[{"given":"Akiyuki","family":"Uzawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Himuro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiko","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.jneuroim.2015.07.013_bb0005","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1158\/1078-0432.CCR-06-1315","article-title":"Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma","volume":"12","author":"Fujita","year":"2006","journal-title":"Clin. Cancer. Res."},{"issue":"1","key":"10.1016\/j.jneuroim.2015.07.013_bb0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jneuroim.2015.07.013_bb0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1348-0421.2005.tb03640.x","article-title":"Autoantibodies to peroxiredoxin I and IV in patients with systemic autoimmune diseases","volume":"49","author":"Karasawa","year":"2005","journal-title":"Microbiol. Immunol."},{"issue":"5","key":"10.1016\/j.jneuroim.2015.07.013_bb0020","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol."},{"issue":"17\u201318","key":"10.1016\/j.jneuroim.2015.07.013_bb0025","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.cca.2010.05.016","article-title":"Immunoluminometric assay for quantification of peroxiredoxin 4 in human serum","volume":"411","author":"Schulte","year":"2010","journal-title":"Clin. Chim. Acta."},{"issue":"6","key":"10.1016\/j.jneuroim.2015.07.013_bb0030","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/nm.2749","article-title":"Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain","volume":"18","author":"Shichita","year":"2012","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.jneuroim.2015.07.013_bb0035","first-page":"24","article-title":"A quantitative proteomic analysis of soluble bronchoalveolar fluid proteins from patients with sarcoidosis and chronic beryllium disease","volume":"24","author":"Silva","year":"2007","journal-title":"Sarcoidosis Vasc. Diffuse. Lung Dis."},{"issue":"2","key":"10.1016\/j.jneuroim.2015.07.013_bb0040","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/cei.12272","article-title":"Serum cytokine and chemokine profiles in patients with myasthenia gravis","volume":"176","author":"Uzawa","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.jneuroim.2015.07.013_bb0045","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/jnnp-2014-309232","article-title":"Serum high mobility group box 1 is upregulated in myasthenia gravis","volume":"86","author":"Uzawa","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"issue":"7","key":"10.1016\/j.jneuroim.2015.07.013_bb0050","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572815300151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572815300151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:25:28Z","timestamp":1759047928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572815300151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":10,"alternative-id":["S0165572815300151"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2015.07.013","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased serum peroxiredoxin 5 levels in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2015.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}